Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

OSR Health subsidiary Vaximm AG completed analysis of two clinical studies evaluating VXM01 in recurrent glioblastoma, confirming the treatment is safe and well-tolerated with successful immune system activation. The data showed no dose-limiting toxicities and indicated dose-dependent immunological activity, supporting the oral DNA vaccine platform's potential across multiple cancer indications.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.